Author: Ashley Ferreira, FSHD Society  The REACH Phase 3 clinical trial, conducted by Fulcrum Therapeutics, aimed to evaluate the efficacy of losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD). Despite promising … Continue reading How Fulcrum Therapeutics’ Phase 3 REACH Clinical Trial Will Continue to Power the Path Forward